Prognostic Value of MiR-137 in Children with Medulloblastoma and Its Regulatory Effect on Tumor Progression

Overview

Journal Neuromolecular Med

Specialty Biochemistry

Date 2021 Aug 19

PMID 34409560

Authors

Wenyuan Ji

Xuan Zhe

Lusheng Li

Yang Cheng

Xueling Zhao

Ping Liang

Chunxi Long

Jianjun Zhou

Affiliations

Soon will be listed here.

Abstract

Medulloblastoma is a malignant tumor with high incidence and poor prognosis in adolescents and children. MicroRNA-137 (miR-137) has been found to be abnormally expressed in cancers such as pancreatic cancer. The purpose of this study is to explore the expression of miR-137 in MB and its role in cell physiological activities to determine the significance of miR-137 in the prognosis of MB. First, the expression of miR-137 in MB tissues and cell lines was analyzed by qRT-PCR. Then the Kaplan-Meier survival curve was used to analyze the significance of miR-137 expression in the prognosis, and the Cox regression model was used to explore the correlation between miR-137 expression and clinical characteristics. The effects of miR-137 on MB cell activities were analyzed by MTT assay, Transwell assays, and flow cytometry. It can be concluded from the results that the expression of miR-137 is down-regulated in MB tissues and cells. The down-regulation of miR-137 was significantly related to the poor prognosis of MB, and significantly related to clinical indicators. Up-regulated miR-137 inhibited cell proliferation, migration, invasion, and cell cycle progression, as well as induced cell apoptosis by targeting KDM1A. This study can conclude that miR-137 may be used as a prognostic biomarker of MB.

Citing Articles

MiRNAs as major players in brain health and disease: current knowledge and future perspectives.

Kapplingattu S, Bhattacharya S, Adlakha Y Cell Death Discov. 2025; 11(1):7.

PMID: 39805813 PMC: 11729916. DOI: 10.1038/s41420-024-02283-x.

References

Bernardo B, Ooi J, Lin R, McMullen J . miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem. 2015; 7(13):1771-92. DOI: 10.4155/fmc.15.107. View

Bi W, Xia M, Wang X . miR-137 suppresses proliferation, migration and invasion of colon cancer cell lines by targeting TCF4. Oncol Lett. 2018; 15(6):8744-8748. PMC: 5950516. DOI: 10.3892/ol.2018.8364. View

Collange N, Brito S, Campos R, Santos E, Botelho R . Treatment of medulloblastoma in children and adolescents. Rev Assoc Med Bras (1992). 2016; 62(4):297. DOI: 10.1590/1806-9282.62.04.297. View

An P, Chen H, Ren H, Su J, Ji M, Kang J . Gastrointestinal Symptoms Onset in COVID-19 Patients in Wuhan, China. Dig Dis Sci. 2020; 66(10):3578-3587. PMC: 7658436. DOI: 10.1007/s10620-020-06693-6. View

Ding F, Zhang S, Gao S, Shang J, Li Y, Cui N . MiR-137 functions as a tumor suppressor in pancreatic cancer by targeting MRGBP. J Cell Biochem. 2018; 119(6):4799-4807. DOI: 10.1002/jcb.26676. View

Du Y, Chen Y, Wang F, Gu L . miR-137 plays tumor suppressor roles in gastric cancer cell lines by targeting KLF12 and MYO1C. Tumour Biol. 2016; 37(10):13557-13569. DOI: 10.1007/s13277-016-5199-3. View

Duan J, Lu G, Li Y, Zhou S, Zhou D, Tao H . miR-137 functions as a tumor suppressor gene in pituitary adenoma by targeting AKT2. Int J Clin Exp Pathol. 2020; 12(5):1557-1564. PMC: 6947140. View

Feng Q, Wu Q, Liu X, Xiong Y, Li H . MicroRNA-137 acts as a tumor suppressor in osteosarcoma by targeting enhancer of zeste homolog 2. Exp Ther Med. 2017; 13(6):3167-3174. PMC: 5450755. DOI: 10.3892/etm.2017.4435. View

Ferrante M, Oliveri Conti G . Environment and Neurodegenerative Diseases: An Update on miRNA Role. Microrna. 2017; 6(3):157-165. DOI: 10.2174/2211536606666170811151503. View

10.

Khatua S, Song A, Citla Sridhar D, Mack S . Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. Curr Neuropharmacol. 2017; 16(7):1045-1058. PMC: 6120114. DOI: 10.2174/1570159X15666171129111324. View

11.

Koschmann C, Bloom K, Upadhyaya S, Geyer J, Leary S . Survival After Relapse of Medulloblastoma. J Pediatr Hematol Oncol. 2016; 38(4):269-73. DOI: 10.1097/MPH.0000000000000547. View

12.

Kumar V, Kumar V, Chaudhary A, Coulter D, McGuire T, Mahato R . Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. Mol Ther Nucleic Acids. 2018; 12:490-503. PMC: 6070673. DOI: 10.1016/j.omtn.2018.06.004. View

13.

Kumar V, Kumar V, McGuire T, Coulter D, Sharp J, Mahato R . Challenges and Recent Advances in Medulloblastoma Therapy. Trends Pharmacol Sci. 2017; 38(12):1061-1084. DOI: 10.1016/j.tips.2017.09.002. View

14.

Li B, Shen M, Yao H, Chen X, Xiao Z . Long Noncoding RNA TP73-AS1 Modulates Medulloblastoma Progression In Vitro And In Vivo By Sponging miR-494-3p And Targeting EIF5A2. Onco Targets Ther. 2019; 12:9873-9885. PMC: 6874156. DOI: 10.2147/OTT.S228305. View

15.

Li K, Pang J, Lau K, Zhou L, Mao Y, Wang Y . MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2012; 23(4):413-25. PMC: 8029115. DOI: 10.1111/bpa.12014. View

16.

Lodewijk L, Prins A, Kist J, Valk G, Kranenburg O, Rinkes I . The value of miRNA in diagnosing thyroid cancer: a systematic review. Cancer Biomark. 2012; 11(6):229-38. DOI: 10.3233/CBM-2012-0273. View

17.

Lu T, Rothenberg M . MicroRNA. J Allergy Clin Immunol. 2017; 141(4):1202-1207. PMC: 5889965. DOI: 10.1016/j.jaci.2017.08.034. View

18.

Nor C, Ramaswamy V . Clinical and pre-clinical utility of genomics in medulloblastoma. Expert Rev Neurother. 2018; 18(8):633-647. DOI: 10.1080/14737175.2018.1503536. View

19.

Pajtler K, Weingarten C, Thor T, Kunkele A, Heukamp L, Buttner R . The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. Acta Neuropathol Commun. 2013; 1:19. PMC: 3893444. DOI: 10.1186/2051-5960-1-19. View

20.

Quinlan A, Rizzolo D . Understanding medulloblastoma. JAAPA. 2017; 30(10):30-36. DOI: 10.1097/01.JAA.0000524717.71084.50. View